Global Adjuvant Therapy Market
Global Adjuvant Therapy Market

Adjuvant Therapy Comprehensive Study by Type (Radiation Therapy, Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy), Application (Hospital, Clinics, Ambulatory Surgical Centers), Side Effect (Fatigue, Pain, Mouth sores, Digestive distress) Players and Region - Global Market Outlook to 2027

Adjuvant Therapy Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Mar 2022 Edition 209 Pages 96 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Adjuvant Therapy Market?

Adjuvant therapy is a term used to encompass all of the extra treatments given in addition to surgery to help reduce the chance of breast cancer recurrence. “Adjuvant” therapy is used after the primary treatment, which is usually surgery, to lessen the chance of breast cancer coming back. Even though surgery was successful at removing all visible cancer, microscopic cancer cells that are undetectable with current methods may remain. Adjuvant therapy for breast cancer is designed to treat “micrometastatic” disease, or breast cancer cells that have escaped the breast and regional lymph nodes, but have not yet established an identifiable metastasis.

The market study is being classified by Type (Radiation Therapy, Chemotherapy, Immunotherapy, Hormone Therapy and Targeted Therapy), by Application (Hospital, Clinics and Ambulatory Surgical Centers) and major geographies with country level break-up.

Merck (United States), Bayer (Germany), PFIZER (United States), Johnson & Johnson (United States), AstraZenca (United Kingdom), TAKEDA (Japan), SANOFI (France), Mylan (United States), AbbVie (United States) and Novartis (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Eli Lilly (United States), Novo Nordisk (Denmark) and Bristol-Myers Squibb (United States).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Adjuvant Therapy market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Adjuvant Therapy market by Type, Application and Region.

On the basis of geography, the market of Adjuvant Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence Of Micrometastatic Disease, Or Breast Cancer
  • Growing Awareness Regarding Health Among Individuals

Market Trend
  • Strong R&D Initiatives From Key Companies Are All Driving Adjuvant Therapy

Restraints
  • Stringent Regulations, And Long Product Approval Process

Opportunities
  • Increase In Awareness About The New Approach To Treat Cancer Leads To Increase In Demand For Adjuvant Therapy
  • Government Favorable Incentives For Cancer Treatment

Challenges
  • High Cost Associated With Adjuvant Therapy
  • Challenges To Develop Adjuvant Therapy Products


Market Leaders and some development strategies
On 11 March 2022, Pfizer Inc. announced the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

On 15 October, 2021, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

Key Target Audience
Adjuvant Therapy, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Adjuvant Therapy Market?
"Rising Prevalence Of Micrometastatic Disease, Or Breast Cancer " is seen as one of major growth factors of Adjuvant Therapy Market in years to come.

2. Can we have customized study for Adjuvant Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Adjuvant Therapy Market?
United States will lead Adjuvant Therapy Market in coming years.
Report Objectives / Segmentation Covered
By Type
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
By Application
  • Hospital
  • Clinics
  • Ambulatory Surgical Centers
By Side Effect
  • Fatigue
  • Pain
  • Mouth sores
  • Digestive distress

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence Of Micrometastatic Disease, Or Breast Cancer
      • 3.2.2. Growing Awareness Regarding Health Among Individuals
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated With Adjuvant Therapy
      • 3.3.2. Challenges To Develop Adjuvant Therapy Products
    • 3.4. Market Trends
      • 3.4.1. Strong R&D Initiatives From Key Companies Are All Driving Adjuvant Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adjuvant Therapy, by Type, Application, Side Effect and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Adjuvant Therapy (Value)
      • 5.2.1. Global Adjuvant Therapy by: Type (Value)
        • 5.2.1.1. Radiation Therapy
        • 5.2.1.2. Chemotherapy
        • 5.2.1.3. Immunotherapy
        • 5.2.1.4. Hormone Therapy
        • 5.2.1.5. Targeted Therapy
      • 5.2.2. Global Adjuvant Therapy by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
      • 5.2.3. Global Adjuvant Therapy by: Side Effect (Value)
        • 5.2.3.1. Fatigue
        • 5.2.3.2. Pain
        • 5.2.3.3. Mouth sores
        • 5.2.3.4. Digestive distress
      • 5.2.4. Global Adjuvant Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Adjuvant Therapy (Price)
      • 5.3.1. Global Adjuvant Therapy by: Type (Price)
  • 6. Adjuvant Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. PFIZER (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZenca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. TAKEDA (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SANOFI (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mylan (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Adjuvant Therapy Sale, by Type, Application, Side Effect and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Adjuvant Therapy (Value)
      • 7.2.1. Global Adjuvant Therapy by: Type (Value)
        • 7.2.1.1. Radiation Therapy
        • 7.2.1.2. Chemotherapy
        • 7.2.1.3. Immunotherapy
        • 7.2.1.4. Hormone Therapy
        • 7.2.1.5. Targeted Therapy
      • 7.2.2. Global Adjuvant Therapy by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
      • 7.2.3. Global Adjuvant Therapy by: Side Effect (Value)
        • 7.2.3.1. Fatigue
        • 7.2.3.2. Pain
        • 7.2.3.3. Mouth sores
        • 7.2.3.4. Digestive distress
      • 7.2.4. Global Adjuvant Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Adjuvant Therapy (Price)
      • 7.3.1. Global Adjuvant Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adjuvant Therapy: by Type(USD Million)
  • Table 2. Adjuvant Therapy Radiation Therapy , by Region USD Million (2016-2021)
  • Table 3. Adjuvant Therapy Chemotherapy , by Region USD Million (2016-2021)
  • Table 4. Adjuvant Therapy Immunotherapy , by Region USD Million (2016-2021)
  • Table 5. Adjuvant Therapy Hormone Therapy , by Region USD Million (2016-2021)
  • Table 6. Adjuvant Therapy Targeted Therapy , by Region USD Million (2016-2021)
  • Table 7. Adjuvant Therapy: by Application(USD Million)
  • Table 8. Adjuvant Therapy Hospital , by Region USD Million (2016-2021)
  • Table 9. Adjuvant Therapy Clinics , by Region USD Million (2016-2021)
  • Table 10. Adjuvant Therapy Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 11. Adjuvant Therapy: by Side Effect(USD Million)
  • Table 12. Adjuvant Therapy Fatigue , by Region USD Million (2016-2021)
  • Table 13. Adjuvant Therapy Pain , by Region USD Million (2016-2021)
  • Table 14. Adjuvant Therapy Mouth sores , by Region USD Million (2016-2021)
  • Table 15. Adjuvant Therapy Digestive distress , by Region USD Million (2016-2021)
  • Table 16. South America Adjuvant Therapy, by Country USD Million (2016-2021)
  • Table 17. South America Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 18. South America Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 19. South America Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 20. Brazil Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 21. Brazil Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 22. Brazil Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 23. Argentina Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 24. Argentina Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 25. Argentina Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 26. Rest of South America Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 27. Rest of South America Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 28. Rest of South America Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 29. Asia Pacific Adjuvant Therapy, by Country USD Million (2016-2021)
  • Table 30. Asia Pacific Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 31. Asia Pacific Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 32. Asia Pacific Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 33. China Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 34. China Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 35. China Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 36. Japan Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 37. Japan Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 38. Japan Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 39. India Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 40. India Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 41. India Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 42. South Korea Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 43. South Korea Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 44. South Korea Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 45. Taiwan Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 46. Taiwan Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 47. Taiwan Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 48. Australia Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 49. Australia Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 50. Australia Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 54. Europe Adjuvant Therapy, by Country USD Million (2016-2021)
  • Table 55. Europe Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 56. Europe Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 57. Europe Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 58. Germany Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 59. Germany Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 60. Germany Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 61. France Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 62. France Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 63. France Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 64. Italy Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 65. Italy Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 66. Italy Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 67. United Kingdom Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 68. United Kingdom Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 69. United Kingdom Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 70. Netherlands Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 71. Netherlands Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 72. Netherlands Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 73. Rest of Europe Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 74. Rest of Europe Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 75. Rest of Europe Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 76. MEA Adjuvant Therapy, by Country USD Million (2016-2021)
  • Table 77. MEA Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 78. MEA Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 79. MEA Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 80. Middle East Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 81. Middle East Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 82. Middle East Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 83. Africa Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 84. Africa Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 85. Africa Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 86. North America Adjuvant Therapy, by Country USD Million (2016-2021)
  • Table 87. North America Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 88. North America Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 89. North America Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 90. United States Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 91. United States Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 92. United States Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 93. Canada Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 94. Canada Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 95. Canada Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 96. Mexico Adjuvant Therapy, by Type USD Million (2016-2021)
  • Table 97. Mexico Adjuvant Therapy, by Application USD Million (2016-2021)
  • Table 98. Mexico Adjuvant Therapy, by Side Effect USD Million (2016-2021)
  • Table 99. Adjuvant Therapy: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Adjuvant Therapy: by Type(USD Million)
  • Table 111. Adjuvant Therapy Radiation Therapy , by Region USD Million (2022-2027)
  • Table 112. Adjuvant Therapy Chemotherapy , by Region USD Million (2022-2027)
  • Table 113. Adjuvant Therapy Immunotherapy , by Region USD Million (2022-2027)
  • Table 114. Adjuvant Therapy Hormone Therapy , by Region USD Million (2022-2027)
  • Table 115. Adjuvant Therapy Targeted Therapy , by Region USD Million (2022-2027)
  • Table 116. Adjuvant Therapy: by Application(USD Million)
  • Table 117. Adjuvant Therapy Hospital , by Region USD Million (2022-2027)
  • Table 118. Adjuvant Therapy Clinics , by Region USD Million (2022-2027)
  • Table 119. Adjuvant Therapy Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 120. Adjuvant Therapy: by Side Effect(USD Million)
  • Table 121. Adjuvant Therapy Fatigue , by Region USD Million (2022-2027)
  • Table 122. Adjuvant Therapy Pain , by Region USD Million (2022-2027)
  • Table 123. Adjuvant Therapy Mouth sores , by Region USD Million (2022-2027)
  • Table 124. Adjuvant Therapy Digestive distress , by Region USD Million (2022-2027)
  • Table 125. South America Adjuvant Therapy, by Country USD Million (2022-2027)
  • Table 126. South America Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 127. South America Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 128. South America Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 129. Brazil Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 130. Brazil Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 131. Brazil Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 132. Argentina Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 133. Argentina Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 134. Argentina Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 135. Rest of South America Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 136. Rest of South America Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 137. Rest of South America Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 138. Asia Pacific Adjuvant Therapy, by Country USD Million (2022-2027)
  • Table 139. Asia Pacific Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 140. Asia Pacific Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 141. Asia Pacific Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 142. China Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 143. China Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 144. China Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 145. Japan Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 146. Japan Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 147. Japan Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 148. India Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 149. India Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 150. India Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 151. South Korea Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 152. South Korea Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 153. South Korea Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 154. Taiwan Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 155. Taiwan Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 156. Taiwan Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 157. Australia Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 158. Australia Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 159. Australia Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 160. Rest of Asia-Pacific Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 161. Rest of Asia-Pacific Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 162. Rest of Asia-Pacific Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 163. Europe Adjuvant Therapy, by Country USD Million (2022-2027)
  • Table 164. Europe Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 165. Europe Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 166. Europe Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 167. Germany Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 168. Germany Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 169. Germany Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 170. France Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 171. France Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 172. France Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 173. Italy Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 174. Italy Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 175. Italy Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 176. United Kingdom Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 177. United Kingdom Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 178. United Kingdom Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 179. Netherlands Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 180. Netherlands Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 181. Netherlands Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 182. Rest of Europe Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 183. Rest of Europe Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 184. Rest of Europe Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 185. MEA Adjuvant Therapy, by Country USD Million (2022-2027)
  • Table 186. MEA Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 187. MEA Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 188. MEA Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 189. Middle East Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 190. Middle East Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 191. Middle East Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 192. Africa Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 193. Africa Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 194. Africa Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 195. North America Adjuvant Therapy, by Country USD Million (2022-2027)
  • Table 196. North America Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 197. North America Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 198. North America Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 199. United States Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 200. United States Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 201. United States Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 202. Canada Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 203. Canada Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 204. Canada Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 205. Mexico Adjuvant Therapy, by Type USD Million (2022-2027)
  • Table 206. Mexico Adjuvant Therapy, by Application USD Million (2022-2027)
  • Table 207. Mexico Adjuvant Therapy, by Side Effect USD Million (2022-2027)
  • Table 208. Adjuvant Therapy: by Type(USD/Units)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adjuvant Therapy: by Type USD Million (2016-2021)
  • Figure 5. Global Adjuvant Therapy: by Application USD Million (2016-2021)
  • Figure 6. Global Adjuvant Therapy: by Side Effect USD Million (2016-2021)
  • Figure 7. South America Adjuvant Therapy Share (%), by Country
  • Figure 8. Asia Pacific Adjuvant Therapy Share (%), by Country
  • Figure 9. Europe Adjuvant Therapy Share (%), by Country
  • Figure 10. MEA Adjuvant Therapy Share (%), by Country
  • Figure 11. North America Adjuvant Therapy Share (%), by Country
  • Figure 12. Global Adjuvant Therapy: by Type USD/Units (2016-2021)
  • Figure 13. Global Adjuvant Therapy share by Players 2021 (%)
  • Figure 14. Global Adjuvant Therapy share by Players (Top 3) 2021(%)
  • Figure 15. Global Adjuvant Therapy share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 18. Merck (United States) Revenue: by Geography 2021
  • Figure 19. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer (Germany) Revenue: by Geography 2021
  • Figure 21. PFIZER (United States) Revenue, Net Income and Gross profit
  • Figure 22. PFIZER (United States) Revenue: by Geography 2021
  • Figure 23. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 25. AstraZenca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZenca (United Kingdom) Revenue: by Geography 2021
  • Figure 27. TAKEDA (Japan) Revenue, Net Income and Gross profit
  • Figure 28. TAKEDA (Japan) Revenue: by Geography 2021
  • Figure 29. SANOFI (France) Revenue, Net Income and Gross profit
  • Figure 30. SANOFI (France) Revenue: by Geography 2021
  • Figure 31. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan (United States) Revenue: by Geography 2021
  • Figure 33. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 34. AbbVie (United States) Revenue: by Geography 2021
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 37. Global Adjuvant Therapy: by Type USD Million (2022-2027)
  • Figure 38. Global Adjuvant Therapy: by Application USD Million (2022-2027)
  • Figure 39. Global Adjuvant Therapy: by Side Effect USD Million (2022-2027)
  • Figure 40. South America Adjuvant Therapy Share (%), by Country
  • Figure 41. Asia Pacific Adjuvant Therapy Share (%), by Country
  • Figure 42. Europe Adjuvant Therapy Share (%), by Country
  • Figure 43. MEA Adjuvant Therapy Share (%), by Country
  • Figure 44. North America Adjuvant Therapy Share (%), by Country
  • Figure 45. Global Adjuvant Therapy: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Merck (United States)
  • Bayer (Germany)
  • PFIZER (United States)
  • Johnson & Johnson (United States)
  • AstraZenca (United Kingdom)
  • TAKEDA (Japan)
  • SANOFI (France)
  • Mylan (United States)
  • AbbVie (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Eli Lilly (United States) , Novo Nordisk (Denmark) , Bristol-Myers Squibb (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation